·AIM: To investigate the possible effects of intracameral bevacizumab on oxidative stress parameters and apoptosis in corneal tissue.·METHODS: In total, 30 rats were assigned randomly into the following thre...·AIM: To investigate the possible effects of intracameral bevacizumab on oxidative stress parameters and apoptosis in corneal tissue.·METHODS: In total, 30 rats were assigned randomly into the following three groups of 10 rats each: a sham group(Group 1; n =10), a control group [Group 2;balanced salt solution(BSS) was administered at 0.01 m L;n =10], and a treatment group(Group 3; bevacizumab was administered at 0.25 mg/0.01 m L; n =10). The total antioxidant status(TAS) and the total oxidant status(TOS) in the corneal tissue and blood samples were measured, and the oxidative stress index(OSI) was calculated. Additionally, corneal tissue histopathology was evaluated for caspase-3 and 8 staining and apoptotic activity.·RESULTS: In the blood samples, the TAS, TOS, and OSI levels were not significantly different(all P 】0.05).Compared with the sham and control groups, the TOS and OSI levels in the corneal tissues were significantly different in the bevacizumab group(all P 【0.05). No statistically significant differences were observed between the sham and control groups(all P 】0.05).However, compared with the sham and control groups,greater immunohistochemical staining for caspases-3and 8 and an elevated level of apoptotic activity were observed in the bevacizumab group.·CONCLUSION: This study revealed that intracameral bevacizumab injections seemed to be systemically safe but may have elicited local toxic effects in the corneal tissue, as indicated by the oxidative stress parameters and histopathological evaluations.展开更多
文摘·AIM: To investigate the possible effects of intracameral bevacizumab on oxidative stress parameters and apoptosis in corneal tissue.·METHODS: In total, 30 rats were assigned randomly into the following three groups of 10 rats each: a sham group(Group 1; n =10), a control group [Group 2;balanced salt solution(BSS) was administered at 0.01 m L;n =10], and a treatment group(Group 3; bevacizumab was administered at 0.25 mg/0.01 m L; n =10). The total antioxidant status(TAS) and the total oxidant status(TOS) in the corneal tissue and blood samples were measured, and the oxidative stress index(OSI) was calculated. Additionally, corneal tissue histopathology was evaluated for caspase-3 and 8 staining and apoptotic activity.·RESULTS: In the blood samples, the TAS, TOS, and OSI levels were not significantly different(all P 】0.05).Compared with the sham and control groups, the TOS and OSI levels in the corneal tissues were significantly different in the bevacizumab group(all P 【0.05). No statistically significant differences were observed between the sham and control groups(all P 】0.05).However, compared with the sham and control groups,greater immunohistochemical staining for caspases-3and 8 and an elevated level of apoptotic activity were observed in the bevacizumab group.·CONCLUSION: This study revealed that intracameral bevacizumab injections seemed to be systemically safe but may have elicited local toxic effects in the corneal tissue, as indicated by the oxidative stress parameters and histopathological evaluations.
